Companion Animal Cardiac Drugs Market Size, Share & Trends Analysis Report By Product (Pimobendan, Furosemide), By Animal Type (Dogs, Cats, Horses), By Indication, By End-use, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

Companion Animal Cardiac Drugs Market Summary

The global companion animal cardiac drugs market size was estimated at USD 1.88 billion in 2024 and is projected to reach USD 3.73 billion by 2033, growing at a CAGR of 8.13% from 2025 to 2033. The industry is driven by several key factors, including the rising prevalence of heart-related disorders in pets, increasing pet humanization and expenditure on pet healthcare, and continuous innovation in cardiology treatments.

Advancements in therapies and growing awareness about the importance of cardiac health in animals are encouraging pet owners to pursue specialized care. The rising penetration of pet insurance is playing a crucial role in driving the growth of the companion animal cardiac drugs market. Providers such as Frank and Trusted Insurance Services Ltd offer diverse insurance plans that cover a broad spectrum of illnesses, including heart disease, cancer, arthritis, diabetes, infections, and other chronic conditions. Such coverage eases the financial strain on pet owners, enabling them to opt for advanced treatments and commit to long-term therapies without hesitation. This increased affordability and access encourage earlier veterinary intervention and consistent use of prescribed medications, thereby expanding the treated patient pool and fueling sustained demand for cardiac drugs.

Moreover, the market growth is accelerated by a combination of clinical, pharmaceutical, and awareness-driven initiatives. Collaborations between veterinary schools and private clinics in provinces such as Quebec and Alberta have facilitated the dissemination of updated cardiac care protocols, enabling veterinarians to diagnose and manage heart conditions more effectively. This has expanded the number of companion animals receiving timely treatment, directly increasing the demand for cardiac drugs. In parallel, pharmaceutical firms like Boehringer Ingelheim and Zoetis Canada have strengthened their provincial distribution networks, ensuring consistent availability of advanced medications. Reliable access encourages veterinarians to prescribe therapies with greater confidence, reducing treatment gaps and improving long-term management of chronic cardiac conditions.

At the same time, awareness campaigns led by organizations such as Humane Canada and the Canadian Veterinary Medical Association (CVMA) have played a crucial role in educating pet owners about early warning signs of heart disease, such as persistent coughing or reduced stamina. These initiatives prompt earlier veterinary consultations and timely initiation of treatment, further enlarging the treated patient pool. Collectively, improved clinical protocols, strong drug distribution infrastructure, and greater public awareness are fueling steady market growth, particularly in key drug categories like ACE inhibitors, diuretics, and beta-blockers.

Furthermore, regulatory approval is becoming increasingly important in the veterinary cardiology market as global demand for specialized animal care continues to grow. In the past, slow and restrictive approval processes limited the adoption of innovative treatments and medical devices, but regulatory agencies such as the U.S. FDA, the European Medicines Agency (EMA), and India’s CDSCO have started to adopt more facilitative approaches to ensure faster access to advanced veterinary solutions.

For instance, in May 2024, the FDA approved several animal drugs, including therapies for canine heart failure. Notably, UpCard-CA1, a torsemide oral solution, received conditional approval for treating pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). Used in combination with established therapies such as pimobendan, spironolactone, and ACE inhibitors, this approval represents a significant advancement in veterinary cardiology by expanding treatment options and improving the management of cardiac conditions in dogs.

Global Companion Animal Cardiac Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global companion animal cardiac drugs market report based on animal type, product, indication, end-use, distribution channel, and region.

• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pimobendan
• Spironolactone and benazepril hydrochloride
• Furosemide
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail
• E-Commerce
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• India
• China
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman

Please note The report will be delivered in 2-3 business days upon order notification. Show more